ReportWire

Tag: WMB

  • WMB Stock Price | Williams Cos. Stock Quote (U.S.: NYSE) | MarketWatch

    WMB Stock Price | Williams Cos. Stock Quote (U.S.: NYSE) | MarketWatch

    [ad_1]

    Williams Cos.

    The Williams Cos., Inc. operates as an energy infrastructure company, which explores, produces, transports, sells and processes natural gas and petroleum products. It operates through the following segments: Transmission and Gulf of Mexico, Northeast G&P, and West. The Transmission and Gulf of Mexico segment consists of interstate natural gas pipelines, the Transco and Northwest Pipelines, as well as natural gas gathering and processing and crude oil production handling and transportation assets in the Gulf Coast region. The Northeast G&P segment includes midstream gathering, processing, and fractionation businesses in the Marcellus Shale region primarily in Pennsylvania and New York, and the Utica Shale region of eastern Ohio. The West segment consists of gas gathering, processing, and treating operations in the Rocky Mountain region of Colorado and Wyoming, the Barnett Shale region of north-central Texas, the Eagle Ford Shale region of south Texas, the Haynesville Shale region of northwest Louisiana, and the Mid-Continent region which includes the Anadarko, Arkoma, and Permian basins. The company was founded by David Williams and Miller Williams in 1908 and is headquartered in Tulsa, OK.

    [ad_2]

    Source link

  • Walgreens stock rallies after profit and sales beat expectations, helped by an acceleration of business in February

    Walgreens stock rallies after profit and sales beat expectations, helped by an acceleration of business in February

    [ad_1]

    Shares of Walgreens Boots Alliance Inc.
    WMB,
    +0.66%
    rallied 2.6% in premarket trading Tuesday, after the health care services and drug store chain reported fiscal second-quarter profit that beat expectations, but fell from a year ago due in part to lower COVID-19 testing and vaccinations. Net income for the quarter to Feb. 28 fell to $703 million, or 81 cents a share, from $883 million, or $1.02 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $1.16 was above the FactSet consensus of $1.10. Sales grew 3.3% to $34.86 billion, well above the FactSet consensus $33.53 billion, boosted by an “acceleration” in February. U.S. Retail Pharmacy sales slipped 0.3% to $27.6 billion, but was above the FactSet consensus of $26.5 billion, while international increased 1.6% to $5.7 billion and U.S. Healthcare revenue more than doubled, to $1.6 billion from $500 million. Gross margin contracted to 20.2% from 22.8%, as cost of sale rose more than sales, up 6.8% to $27.81 billion. Looking ahead, the company affirmed its fiscal 2023 adjusted EPS guidance range of $4.45 to $4.65, which surrounds the FactSet consensus of $4.50. The stock has shed 11.8% year to date through Monday, while the Consumer Staple Select Sector SPDR exchange-traded fund
    XLP,
    +0.53%
    has eased 1.6% and the Dow Jones Industrial Average
    DJIA,
    +0.60%
    has slipped 2.2%.

    [ad_2]

    Source link